X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cholangiocarcinoma (72) 72
index medicus (40) 40
humans (35) 35
cca (30) 30
cancer (22) 22
intrahepatic cholangiocarcinoma (19) 19
male (18) 18
oncology (18) 18
female (17) 17
cholangiocarcinoma - pathology (15) 15
gastroenterology & hepatology (15) 15
cell line, tumor (14) 14
expression (13) 13
middle aged (13) 13
animals (12) 12
apoptosis (12) 12
cholangiocarcinoma - genetics (12) 12
prognosis (12) 12
chemotherapy (11) 11
metastasis (11) 11
parasitic diseases (11) 11
primary sclerosing cholangitis (11) 11
proliferation (11) 11
bile duct neoplasms - pathology (10) 10
liver (10) 10
liver cancer (10) 10
aged (9) 9
analysis (9) 9
cholangiocarcinoma - drug therapy (9) 9
cholangiocarcinoma - metabolism (9) 9
gastroenterology and hepatology (9) 9
hepatocellular carcinoma (9) 9
mice (9) 9
review (9) 9
adult (8) 8
bile duct neoplasms - genetics (8) 8
bile duct neoplasms - metabolism (8) 8
cardiovascular system (8) 8
cholangiocarcinoma - mortality (8) 8
fungi (8) 8
gene expression (8) 8
growth (8) 8
hcc (8) 8
hepatocellular-carcinoma (8) 8
invasion (8) 8
migration (8) 8
article (7) 7
bile duct neoplasms - drug therapy (7) 7
cca, cholangiocarcinoma (7) 7
diagnosis (7) 7
management (7) 7
progression (7) 7
survival (7) 7
therapy (7) 7
activation (6) 6
antineoplastic agents - pharmacology (6) 6
biomarker (6) 6
cell proliferation (6) 6
gene expression regulation, neoplastic (6) 6
mice, nude (6) 6
proteins (6) 6
research paper (6) 6
review article (6) 6
surgery (6) 6
xenograft model antitumor assays (6) 6
bile duct neoplasms - diagnosis (5) 5
bile duct neoplasms - mortality (5) 5
biochemistry & molecular biology (5) 5
breast-cancer (5) 5
cell biology (5) 5
cells (5) 5
cholangiocarcinoma - diagnosis (5) 5
disease progression (5) 5
gemcitabine (5) 5
liver transplantation (5) 5
lung-cancer (5) 5
medicine, research & experimental (5) 5
micrornas (5) 5
multivariate analysis (5) 5
original (5) 5
original article (5) 5
perihilar cholangiocarcinoma (5) 5
proportional hazards models (5) 5
risk factors (5) 5
risk-factors (5) 5
signal transduction (5) 5
bile duct neoplasms - surgery (4) 4
bile ducts, intrahepatic (4) 4
biotechnology & applied microbiology (4) 4
ca19-9 (4) 4
carcinogenesis (4) 4
carcinoma (4) 4
cardiovascular diseases (4) 4
cell growth (4) 4
cell-proliferation (4) 4
chemoradiation (4) 4
cholangiocarcinoma - blood (4) 4
cholangiocarcinoma - surgery (4) 4
cholangiocytes (4) 4
disease (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 4, pp. 1021 - 1031.e15
Background & Aims Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%−10% of primary liver cancers. We characterized its... 
Gastroenterology and Hepatology | CCA | Gene Expression | Hepatic | Genetic Analysis | SURVIVAL | INTRAHEPATIC CHOLANGIOCARCINOMA | PHASE-II | RECEPTOR | EXPRESSION PROFILES | BREAST-CANCER | BILIARY CANCER | LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | MUTATIONS | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Proto-Oncogene Proteins p21(ras) | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Tumor Microenvironment | Male | Bile Duct Neoplasms - enzymology | Time Factors | Bile Duct Neoplasms - genetics | Cholangiocarcinoma - enzymology | Precision Medicine | Genetic Predisposition to Disease | Risk Assessment | Risk Factors | ras Proteins - antagonists & inhibitors | Survival Rate | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Phenotype | Belgium | Cell Line, Tumor | Cholangiocarcinoma - genetics | Mutation | Quinazolines - pharmacology | Trastuzumab | Cluster Analysis | Protein-Tyrosine Kinases - antagonists & inhibitors | ras Proteins - genetics | Prognosis | United States | Laser Capture Microdissection | Molecular Targeted Therapy | Patient Selection | Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacology | Bile Duct Neoplasms - drug therapy | Proto-Oncogene Proteins - antagonists & inhibitors | Bile Ducts, Intrahepatic - pathology | Cholangiocarcinoma - mortality | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | Proto-Oncogene Proteins - genetics | Chi-Square Distribution | Bile Ducts, Intrahepatic - enzymology | Cholangiocarcinoma - pathology | Cholangiocarcinoma - drug therapy | Proto-Oncogene Proteins B-raf - genetics | Bile Duct Neoplasms - mortality | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Bile Duct Neoplasms - pathology | Protein-Tyrosine Kinases - analysis | Queensland | Tyrosine | Genes | Amino acids | Transforming growth factors | Gene expression | Liver cancer | Epidermal growth factor | Analysis | Phenols | Genetic research | Genetic aspects | Health aspects | Cancer
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 03/2015, Volume 42, Issue 3, pp. 293 - 304
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2018, Volume 102, pp. 10 - 22
Palbociclib is an oral cyclin-dependent kinase 4/6 inhibitor, which is efficacious in treating breast cancer. Currently, there are numerous active clinical... 
CCA | HCC | ATM | Radiosensitivity | PP5 | Palbociclib | TUMOR | BREAST-CANCER | REPAIR | PPP5C | ONCOLOGY | PROTEIN PHOSPHATASE 5 | CDK4/6 INHIBITOR | GROWTH | Yuan (China) | Phosphatases | DNA damage | Liver | Radiation | Hepatoma | Radiotherapy | DNA repair | DNA | Ataxia | Ataxia telangiectasia | Genetic aspects | Cancer
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 10/2018, Volume 504, Issue 4, pp. 654 - 659
Cholangiocarcinoma (CCA) is the as the most frequently observed biliary tract malignancy, which has low survival rate in addition to constrained treatment... 
LncRNA | Cholangiocarcinoma (CCA) | MYC | Lnc-EPIC1 | BIOPHYSICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | BILIARY-TRACT CANCERS | PROGRESSION | Chemotherapy | RNA | Growth | Cancer
Journal Article
Journal Article
by Li, Z and Li, X and Du, X and Zhang, HH and Wu, ZY and Ren, KW and Han, XW
ONCOLOGY RESEARCH, ISSN 0965-0407, 2019, Volume 27, Issue 6, pp. 663 - 672
Cholangiocarcinoma (CCA) is the second most common primary hepatobiliary carcinoma. The long noncoding RNA (IncRNA) small nucleolar RNA host gene 1 (SNHG1) has... 
Long noncoding RNAs (lncRNAs) SNHG1 | MANAGEMENT | Toll-like receptor 4 (TLR4) | CELL-PROLIFERATION | NONCODING RNA SNHG1 | LUNG-CANCER | INVASION | INHIBITION | ONCOLOGY | Cholangiocarcinoma (CCA) | miR-140 | NF-kappa B signaling | NF-KAPPA-B | EXPRESSION | CONTRIBUTES | PROGRESSION
Journal Article
BBA - Molecular Basis of Disease, ISSN 0925-4439, 04/2018, Volume 1864, Issue 4, pp. 1335 - 1344
Cholangiocarcinoma (CCA) is an aggressive tumor type affecting cholangiocytes. CCAs frequently arise under certain cholestatic liver conditions. Intrahepatic... 
Cholangiocarcinoma (CCA) | FXR | TGR5 | Therapy | Bile acids | BIOCHEMISTRY & MOLECULAR BIOLOGY | FARNESOID-X RECEPTOR | NUCLEAR RECEPTOR | CHOLANGIOCYTES | GASTROINTESTINAL CANCER | BIOPHYSICS | LIVER | DISEASE | GROWTH | EXPRESSION | BILE-ACIDS | PRIMARY SCLEROSING CHOLANGITIS | Epithelial Cells - metabolism | Receptors, G-Protein-Coupled - metabolism | Bile Ducts - metabolism | Humans | Middle Aged | Male | Receptors, G-Protein-Coupled - agonists | Bile Ducts - cytology | Aged, 80 and over | Chenodeoxycholic Acid - pharmacology | Female | Bile Duct Neoplasms - drug therapy | Bile Ducts - drug effects | Bile Acids and Salts - metabolism | Epithelial Cells - pathology | Mitochondria - metabolism | Receptors, Cytoplasmic and Nuclear - agonists | Mitochondria - drug effects | Chenodeoxycholic Acid - analogs & derivatives | Disease Progression | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Cholic Acids - pharmacology | Cholangiocarcinoma - pathology | Gastrointestinal Agents - pharmacology | Animals | Cholangiocarcinoma - drug therapy | Mice, Nude | Gastrointestinal Agents - therapeutic use | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Mice | Bile Duct Neoplasms - pathology | Bile Ducts - pathology | Energy Metabolism - drug effects | Cohort Studies | Receptors, Cytoplasmic and Nuclear - metabolism
Journal Article
Journal Article
Scandinavian Journal of Gastroenterology, ISSN 0036-5521, 05/2019, Volume 54, Issue 5, pp. 640 - 645
Background: Endoscopic biliary drainage is the standard of care for patients with cholangiocarcinoma (CCA)-induced, obstructive jaundice. Self-expanding metal... 
CCA | plastic | SEMS | TRIAL | DIAGNOSIS | BILE-DUCT | MANAGEMENT | CISPLATIN | OBSTRUCTION | GASTROENTEROLOGY & HEPATOLOGY | GEMCITABINE
Journal Article
Gastroenterology, ISSN 0016-5085, 03/2018, Volume 154, Issue 4, pp. 1066 - 1079.e5
Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new therapeutic agents are needed. We performed a screen to identify small-molecule compounds that... 
Organoid | Bile Duct Cancer | DNAJB5 | AUY922 | BILIARY-TRACT CANCER | INTRAHEPATIC CHOLANGIOCARCINOMA | ADVANCED SOLID TUMORS | PANCREATIC-CANCER | ACQUIRED-RESISTANCE | I DOSE-ESCALATION | TYROSINE KINASE INHIBITORS | HSP90 INHIBITORS | PROSTATE-CANCER | GASTROENTEROLOGY & HEPATOLOGY | MICRORNA EXPRESSION | Humans | Gene Expression Regulation, Neoplastic | MicroRNAs - metabolism | Cholangiocarcinoma - metabolism | Dose-Response Relationship, Drug | Transfection | Organoids | Time Factors | Antineoplastic Agents - pharmacology | HSP90 Heat-Shock Proteins - genetics | Bile Duct Neoplasms - genetics | Tumor Cells, Cultured | Nuclear Proteins - genetics | Bile Duct Neoplasms - drug therapy | Cell Survival - drug effects | HSP40 Heat-Shock Proteins - metabolism | Bile Duct Neoplasms - metabolism | HSP40 Heat-Shock Proteins - genetics | Isocitrate Dehydrogenase - genetics | Transcription Factors - genetics | Mice, SCID | Xenograft Model Antitumor Assays | Cholangiocarcinoma - pathology | Drug Resistance, Neoplasm - genetics | Animals | Cholangiocarcinoma - drug therapy | Signal Transduction - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Cell Line, Tumor | Cholangiocarcinoma - genetics | HSP90 Heat-Shock Proteins - metabolism | Mice, Inbred NOD | MicroRNAs - genetics | Bile Duct Neoplasms - pathology | Mutation | FFPE, formalin-fixed paraffin-embedded | FGFR, fibroblast growth factor receptor | WT, wild type | PDO, patient-derived organoid | GI, growth inhibition | miRNA, microRNA | HTS, high-throughput screen | DMSO, dimethyl sulfoxide | HSP, heat shock protein | iCCA, intrahepatic cholantiocarcinoma | CCA, cholangiocarcinoma
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2016, Volume 65, Issue 4, pp. 849 - 855
Journal Article